文献速递肝病消化道肿瘤与早癌

大规模多中心血清代谢物生物标志物鉴定研究用于肝细胞癌早期检测

A Large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma.
PubMed 文献 · Hepatology · 2018-01-02

研究在中国多中心招募1448名受试者,采用液相色谱-质谱代谢组学方法筛选并验证肝细胞癌血清代谢物标志物。由苯丙氨酰-色氨酸和甘氨胆酸组成的标志物组合在区分肝细胞癌与肝硬化高危人群时诊断性能优于甲胎蛋白,并能提高临床前肝细胞癌及小肝癌的检出。

要点

  • 血清苯丙氨酰-色氨酸与甘氨胆酸组合在发现集、测试集和验证集队列1中区分肝细胞癌与肝硬化的AUC分别为0.930、0.892和0.807,均高于甲胎蛋白的0.657、0.725和0.650。
  • 该组合检测临床前肝细胞癌的灵敏度范围为80.0%至70.3%,与甲胎蛋白联合可改善临床诊断前肝细胞癌的风险预测。
  • 该组合区分小肝癌的AUC为0.866,高于甲胎蛋白的0.682;在测试集中使80.6%的甲胎蛋白假阴性肝细胞癌患者被正确诊断,并在验证集中得到印证。

核心结论

  • 发现并验证的血清代谢物标志物组合对高危人群肝细胞癌的早期检测表现出良好的诊断性能。

研究设计与样本

  • 从中国多个中心招募1448名受试者,包括健康对照以及慢性乙型肝炎病毒感染、肝硬化和肝细胞癌患者。
  • 采用基于液相色谱-质谱的代谢组学方法表征受试者血清代谢谱,并筛选和验证肝细胞癌生物标志物。

主要发现

  • 由苯丙氨酰-色氨酸和甘氨胆酸组成的血清代谢物标志物组合,在区分肝细胞癌与肝硬化高危人群时诊断性能高于甲胎蛋白。
  • 在发现集、测试集和验证集队列1中,该组合的受试者操作特征曲线下面积分别为0.930、0.892和0.807,甲胎蛋白分别为0.657、0.725和0.650。
  • 在嵌套病例对照研究中,该组合检测临床前肝细胞癌的灵敏度范围为80.0%至70.3%,与甲胎蛋白联合对临床诊断前肝细胞癌提供更好的风险预测。
  • 该组合区分小肝癌的受试者操作特征曲线下面积为0.866,甲胎蛋白为0.682。
  • 在测试集中,该组合正确诊断了80.6%的甲胎蛋白假阴性肝细胞癌患者,并在验证集中得到印证。

关键数值与推荐

  • 肝细胞癌与肝硬化高危人群区分:发现集该组合AUC 0.930 vs 甲胎蛋白0.657,测试集0.892 vs 0.725,验证集队列1 0.807 vs 0.650。
  • 临床前肝细胞癌检测灵敏度范围为80.0%至70.3%。
  • 小肝癌区分:该组合AUC 0.866 vs 甲胎蛋白0.682。
  • 测试集中该组合正确诊断80.6%的甲胎蛋白假阴性肝细胞癌患者。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hepatocellular carcinoma (HCC) is the third most lethal cancer worldwide. The lack of effective biomarkers for the early detection of HCC results in unsatisfactory curative treatments. Here, metabolite biomarkers were identified and validated for HCC diagnosis. A total of 1,448 subjects, including healthy controls and patients with chronic hepatitis B virus infection, liver cirrhosis, and HCC, were recruited from multiple centers in China. Liquid chromatography-mass spectrometry-based metabolomics methods were used to characterize the subjects' serum metabolic profiles and to screen and validate the HCC biomarkers. A serum metabolite biomarker panel including phenylalanyl-tryptophan and glycocholate was defined. This panel had a higher diagnostic performance than did α-fetoprotein (AFP) in differentiating HCC from a high-risk population of cirrhosis, such as an area under the receiver-operating characteristic curve of 0.930, 0.892, and 0.807 for the panel versus 0.657, 0.725, and 0.650 for AFP in the discovery set, test set, and cohort 1 of the validation set, respectively. In the nested case-control study, this panel had high sensitivity (range 80.0%-70.3%) to detect preclinical HCC, and its combination with AFP provided better risk prediction of preclinical HCC before clinical diagnosis. Besides, this panel showed a larger area under the receiver-operating characteristic curve than did AFP (0.866 versus 0.682) to distinguish small HCC, and 80.6% of the AFP false-negative patients with HCC were correctly diagnosed using this panel in the test set, which was corroborated by the validation set. The specificity and biological relevance of the identified biomarkers were further evaluated using sera from another two cancers and HCC tissue specimens, respectively. Conclusion: The discovered and validated serum metabolite biomarker panel exhibits good diagnostic performance for the early detection of HCC from at-risk populations. (Hepatology 2018;67:662-675).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Luo P, Yin P, Hua R, et al. A Large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma. Hepatology. 2018. PMID: 28960374. doi:10.1002/hep.29561

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。